OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
SHIEF
Shield Therapeutics PLC
Ordinary Shares
0.0346
0.0015
4.53%
0.0318 / 0.0374 (10000 x 10000)
Real-Time Best Bid & Ask: 05:00pm 06/13/2025
Delayed (15 Min) Trade Data: 12:00am 06/13/2025
0.0346
0.0346 - 0.0346
10,010
Market Cap calculated only for this class of securities.
36,042,491
Real-Time Level 2 Quote
Bid
Ask
MPID MPID | Bid Price Bid Price | Size Size | Time Time |
|---|---|---|---|
MCAP LLC | 0.0318 | 10,000 | 06/13 |
CANACCORD GENUITY LLC. | 0.0125 | 10,000 | 06/13 |
StoneX Financial Inc. | 0.0125 | 10,000 | 06/13 |
Citadel Securities | 0.0064 | 10,000 | 06/13 |
VIRTU Americas LLC | 0.0001 | 10,000 | >year |
MPID MPID | Ask Price Ask Price | Size Size | Time Time |
|---|---|---|---|
MCAP LLC | 0.0374 | 10,000 | 06/13 |
Citadel Securities | 0.0671 | 10,000 | 06/13 |
StoneX Financial Inc. | 0.0671 | 10,000 | 06/13 |
VIRTU Americas LLC | 0.2354 | 2,500 | 06/13 |
CANACCORD GENUITY LLC. | 0.90 | 1,000 | 06/13 |
Trade Data
Date Date | Timestamp Timestamp | Price Price | $ Change $ Change | Volume Volume |
|---|---|---|---|---|
| 06/13/2025 | 12:07:28 | 0.0346 | 0.00 | 10,000 |
| 06/03/2025 | 11:40:37 | 0.0331 | -0.00 | 4,000 |
| 01/31/2025 | 09:30:09 | 0.034 | -0.00 | 4,020 |
| 12/27/2024 | 14:20:15 | 0.0345 | -0.00 | 4,000 |
| 12/12/2024 | 12:18:11 | 0.0355 | -0.00 | 1,000 |
News
Result of 2025 AGMOTC Disclosure & News Service | 05/22/2025
Audited results for the year ended 31 December 2024OTC Disclosure & News Service | 04/24/2025
Licence Agreement in Japan for ACCRUFeR®OTC Disclosure & News Service | 04/22/2025
Filings and Disclosure
Company Description
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield's lead product, Accrufer®/Feraccru®, has been approved for use in the United States, European Union, UK, Switzerland, Australia and Canada and has exclusive IP rights until the mid-2030s. The Group has launched Accrufer® in the US. Feraccru® is being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer®/Feraccru® in China, Hong Kong, Macau, and Taiwan, Korea Pharma Co., Ltd. in the Republic of Korea and with KYE Pharmaceuticals Inc in Canada.
Videos
This company has not added any videos
Joined OTCQB 05/2024
The Company Profile data was verified by the issuer within the previous 6 months.
This security is not a Penny Stock as defined in SEC Rule 240.3a51-1.
This company has certified to OTC Markets Group that it is eligible to rely on the exemption from registration under Securities and Exchange Act Rule 12g3-2(b).
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Loading...
Symbol
OTCM
Last
51.15
Change
0.15 (0.29%)
Bid
51.15
Ask
51.40
Volume
13900
Time
00:00
